Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
delta-[1-13C] gluconolactone is a carbon-13 isotopically labeled research imaging probe used in hyperpolarized magnetic resonance spectroscopy (MRS) to assess metabolic flux through the pentose phosphate pathway (PPP). The compound is a labeled version of delta-gluconolactone (D-glucono-1,5-lactone) that enters cells via glucose transporters and is subsequently phosphorylated to 6-phospho-delta-[1-13C]gluconolactone. It serves as a substrate for the enzyme 6-phosphogluconolactonase (PGLS), which converts it to [1-13C]6-phosphogluconate (6PG). This metabolic conversion allows researchers to visualize dynamic PPP activity in vivo. Preclinical studies, primarily conducted at institutions like UCSF, have utilized this probe to image glioblastoma (GBM), specifically to monitor TERT-associated changes in redox metabolism and evaluate response to therapies such as temozolomide or GABPB1 targeting.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on delta-[1-13C] gluconolactone.